Sumant Ramachandra, M.D., Ph.D., CEO

April 9 | 12:00pm | Salone dei Cavalieri, Section 2

Los Angeles, CA,


ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA), are specifically designed to prevent antigen escape, overcome the immunosuppressive tumor microenvironment, and deplete pathogenic B cells. The company’s technology is based on the work of pioneering UCLA scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D.

By using this website you agree to accept our Privacy Policy and Terms & Conditions